Third, none of the panels used in this study included genes associated with familial breast cancer nor did they determine copy number alterations, limiting potential targeted therapies that could be recommended such as PARP inhibitors or HER2 targeted therapies Fourth, no blood samples were collected at the time of the study completion, so no match plasma vs. tissue results could be analyzed in order to test liquid biopsy utility in our series (23). The gene discussed is ERBB2; the disease is breast cancer.